1. Home
  2. CINGW vs GPOR Comparison

CINGW vs GPOR Comparison

Compare CINGW & GPOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • GPOR
  • Stock Information
  • Founded
  • CINGW N/A
  • GPOR 1997
  • Country
  • CINGW United States
  • GPOR United States
  • Employees
  • CINGW 13
  • GPOR N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • GPOR Oil & Gas Production
  • Sector
  • CINGW Health Care
  • GPOR Energy
  • Exchange
  • CINGW Nasdaq
  • GPOR Nasdaq
  • Market Cap
  • CINGW N/A
  • GPOR N/A
  • IPO Year
  • CINGW 2021
  • GPOR N/A
  • Fundamental
  • Price
  • CINGW $0.04
  • GPOR $172.67
  • Analyst Decision
  • CINGW
  • GPOR Buy
  • Analyst Count
  • CINGW 0
  • GPOR 7
  • Target Price
  • CINGW N/A
  • GPOR $210.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • GPOR 261.0K
  • Earning Date
  • CINGW N/A
  • GPOR 04-29-2025
  • Dividend Yield
  • CINGW N/A
  • GPOR N/A
  • EPS Growth
  • CINGW N/A
  • GPOR N/A
  • EPS
  • CINGW N/A
  • GPOR N/A
  • Revenue
  • CINGW N/A
  • GPOR $909,219,000.00
  • Revenue This Year
  • CINGW N/A
  • GPOR $64.87
  • Revenue Next Year
  • CINGW N/A
  • GPOR $7.87
  • P/E Ratio
  • CINGW N/A
  • GPOR N/A
  • Revenue Growth
  • CINGW N/A
  • GPOR N/A
  • 52 Week Low
  • CINGW N/A
  • GPOR $130.02
  • 52 Week High
  • CINGW N/A
  • GPOR $201.18
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • GPOR 49.43
  • Support Level
  • CINGW N/A
  • GPOR $156.94
  • Resistance Level
  • CINGW N/A
  • GPOR $172.53
  • Average True Range (ATR)
  • CINGW 0.00
  • GPOR 8.93
  • MACD
  • CINGW 0.00
  • GPOR -0.45
  • Stochastic Oscillator
  • CINGW 0.00
  • GPOR 51.07

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: